Demerger could fetch higher valuations for Piramal Pharma

| 0 comments

Ajay Piramal does it again, sells data analytics business for a profit of  Rs 3,350 crore - BusinessToday

Ajay Piramal is an Indian billionaire industrialist, and the chairman of the Piramal Group, a conglomerate with interests in pharmaceutical, financial services, real estate, healthcare analytics and glass packaging.

The company is focussing on growth and is scouting for more acquisitions
Topics
Piramal Enterprises | Piramal Group | Ajay Piramal
The demerger and consolidation of the pharma business of Piramal Enterprises under Piramal Pharma (PPL) is a positive move for shareholders both from the valuation and growth perspectives. Given the holding company structure, analysts were valuing the pharma segment at a 20 per cent discount.

With a separate listed entity, the estimated enterprise value of PPL could move up from the Rs 31,500 crore that analysts at Motilal Oswal Research had pegged for the pharma business. A year ago the Carlyle Group had picked up a 20 per cent stake in the pharma business valuing the company at $2.8

Leave a Reply

Required fields are marked *.